A method for translocation of a peptide through a nanopore, wherein the method comprises translocating the peptide in the presence of an oligonucleotide translocase, wherein the peptide is comprised by a peptide-oligonucleotide complex, wherein the peptide is linked to an oligonucleotide, wherein the oligonucleotide translocase is associated to the oligonucleotide during at least part of the translocation.

A method for reducing senescence-positive cells in a subject includes a step of identify a subject having increased expression of p16INK4a or at risk for increased of p16INK4a. A fasting-mimicking diet is administered to the subject for a first time period.

Therapeutic methods and medicines may be developed by identifying a gene responsible for progressive supranuclear palsy, as may effective therapeutic methods and medicines. A medicine for progressive supranuclear palsy may contain a compound for inhibiting the expression of a filamin-A gene is provided. Also provided is an assessment system that uses cells expressing filamin-A, which is used in the search for medicaments for progressive supranuclear palsy or their candidates.

The present invention provides a method comprising a step of estimating the kidney function of an arbitrary subject by a regression analysis which employs the amount of a D, L-amino acid in a biological sample from the arbitrary subject as an explanatory variable and employs the amount of filtrated glomeruli in the arbitrary subject as an object variable, by employing a previously determined formula (I): Y=a.sub.1.Math.X.sub.1+a.sub.2.Math.X.sub.2+ . . . +a.sub.n.Math.X.sub.n+b (I) [wherein a.sub.1 to a.sub.n independently represent a constant obtained by the regression analysis; X.sub.1 to X.sub.n independently represent a variable of the amount of the D,L-amino acid which is selected by the regression analysis; and b represents a constant obtained by the regression analysis] on the basis of the Y value calculated from the amount of the D, L-amino acid in the biological sample from the object to be evaluated. Also provided is a system for carrying out the method.

The invention relates to the method for building nanoparticle-based drug carriers and the nanoparticle based drug delivery system able to manipulate the corresponding protein corona for specific and potent drug delivery to cancer cells.

The disclosure provides methods that facilitate disease management by providing for early detection of metabolic changes that differentiate critically ill-COVID-19 patients under mechanical ventilation at the intensive care unit (ICU) who are likely to exhibit faster recovery.

The present invention relates to the field of protein characterization, and in particular to methods for identifying critical quality attributes of therapeutic proteins expressed in host cells by implementing a workflow including using a competitive binding assay with insufficient antigen followed by SCX-MS.

The present disclosure provides a method of detecting the presence of a hypnozoite stage of Plasmodium vivax in a liver cell. In addition, the present disclosure provides compositions and methods of detecting the presence of a latent Plasmodium vivax infection in a subject and for treating the subject detected to be infected.

The invention provides anti-Tau antibodies and methods of using the same.

The present invention pertains to methods for characterizing proteins in a sample using native capillary electrophoresis-mass spectrometry. The present invention pertains to methods for detecting and/or discriminating between post-translational modification variants of an antibody of interest in a sample, detecting and/or discriminating between antibodies in an antibody mixture, and characterizing monospecific antibody side products in a bispecific antibody sample.